Document ID: chunk:federal_register_of_legislation:F2022L01391:reg:9:p4
Version: federal_register_of_legislation:F2022L01391
Segment Type: reg
Provision Reference: reg 9 (pt 4/4)
Character Range: 12449–14460

joint instability of the affected shoulder, or dislocation or subluxation of the affected shoulder joint before the clinical worsening of rotator cuff syndrome;
(31)      having an infection of the subacromial bursa or subdeltoid bursa of the affected shoulder at the time of the clinical worsening of rotator cuff syndrome;
(32)      having an autoimmune disease from the specified list of autoimmune diseases, involving the shoulder joint or associated bursae of the affected side, before the clinical worsening of rotator cuff syndrome;
Note: specified list of autoimmune diseases is defined in the Schedule 1 - Dictionary.
(33)      having gout involving the affected shoulder at the time of the clinical worsening of rotator cuff syndrome;
(34)      having acquired scapular dyskinesis of the affected side at the time of the clinical worsening of rotator cuff syndrome;
Note: acquired scapular dyskinesis is defined in the Schedule 1 – Dictionary.
(35)      having smoked at least 20 pack-years of tobacco products before the clinical worsening of rotator cuff syndrome;
Note: one pack-year is defined in the Schedule 1 – Dictionary.
(36)      having diabetes mellitus before the clinical worsening of rotator cuff syndrome;
(37)      having dyslipidaemia before the clinical worsening of rotator cuff syndrome;
Note: dyslipidaemia is defined in the Schedule 1 – Dictionary.
(38)      taking a glucocorticoid drug as specified before the clinical worsening of rotator cuff syndrome;
Note: taking a glucocorticoid drug as specified is defined in the Schedule 1 – Dictionary.
(39)      taking a fluoroquinolone antibiotic within the 60 days before the clinical worsening of rotator cuff syndrome;
(40)      taking an aromatase inhibitor for at least 4 weeks within the 2 years before the clinical worsening of rotator cuff syndrome;
Note: Examples of aromatase inhibitors include anastrozole, exemestane and letrozole.
(41)      inability to obtain appropriate clinical management for rotator cuff syndrome.